Follow us on:

The biosimilar market is expected to grow between 22% and 30% annually in Europe within the coming years. The main driver of this growth...

The lockdown generated by the pandemic in most of the world has significantly altered the way we engage with customers. Deals that were...

Facing the unexpected At the end of February, coming back from London, where I moderated the second session of Pharma Synergy 2020, I was...

A few days ago, Biopharmalinks (Emergpharma, www.emergpharmalinks.com) finished the first part of its ambitious research on biosimilars...

Risks associated with the decision to develop biosimilars As we have seen in recent years, many companies that have developed or...

As we insist on almost all our articles, biosimilars are not an option, but a need. As commented in our presentation last Thursday at...

In previous articles, I have shown some ideas about the past, present, and future of biosimilars. Once again, I would like to insist on...

"After reviewing the existing literature on possible therapeutic options; treating patients with severe or critical Covid-19-induced...

We are witnessing the collapse of the units of intensive care in hospitals. The coronavirus crisis, that apparently "nobody saw coming"...

Preliminary results of the Emergpharma’s “biosimilar 255 tracking January 2020” Emergpharma has just completed the first phase of its...

Conclusions of a survey on biosimilar adoption in the EU Top 5 A few weeks ago I published an article in Biosimilar Development on the...

Healthcare companies, mostly small and medium-size, are making relevant errors that seriously compromise their chances of success in new...

Recently we were hired by a pharmaceutical company with headquarters in an Asian country that had decided to expand to European markets....

Biosimilars have traditionally been seen by large pharmaceutical companies as a threat to their most profitable products and the priority...

The available data on biosimilars in Europe are still insufficient to carry out a rigorous analysis to show correlations. However, given...

Twelve years after the launch of the first biosimilar in Europe, there are still limited data available on the medium-term impact of the...

Mabthera (rituximab) has faced the launch of first biosimilars in EU markets between 2016 and 2018. Some outcomes from Emergpharma's...

Preliminary results of the First Report on the German market of oncological medicines 2016-2018 performed by Emergpharma show some...

A sub-study from the report “German generics market 2016-2018” recently published by Emergpharma shows interesting facts regarding the...

German generics market is the biggest in Europe in terms of values and units. It is also one of the most dynamic and with the largest...